Products Umeclidinium + Vehicle
Umeclidinium + Vehicle Phase 2 Completed ⚡ Active Mar 7, 2016 → Dec 8, 2016
About Umeclidinium + Vehicle Umeclidinium + Vehicle is a phase 2 stage product being developed by GSK plc for Hyperhidrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02673619. Target conditions include Hyperhidrosis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02673619 Phase 2 Completed Mar 7, 2016 Dec 8, 2016 Hyperhidrosis
Product Company Stage Hype Score Dose 1 of glycopyrrolate, 2.0% QD + Dose 2 of glycopyrrolate, 3.0% QD + Dose 1 of glycopyrronium, 2.5% QD + Dose 2 of glycopyrronium, 3.75% QD Journey Medical Phase 2 glycopyrronium Topical Wipes Journey Medical Phase 3 Glycopyrronium Topical Wipes Journey Medical Phase 3 glycopyrrolate, 1.0% + glycopyrrolate, 2.0% + glycopyrrolate, 3.0% + glycopyrrolate, 4.0% Journey Medical Phase 2 glycopyrronium Topical Wipes Journey Medical Phase 3 Glycopyrronium cloth, 2.4% + Vehicle Journey Medical Phase 2 BBI-4000 gel, 5% + BBI-4000 gel, 10% + BBI-4000 gel, 15% + Vehicle (Placebo) Botanix Pharmaceuticals Phase 2 BBI-4000 Gel, 5% + BBI-4000 Gel, 10% + BBI-4000 Gel, 15% + Vehicle Botanix Pharmaceuticals Phase 2 BBI-4000, 15% Botanix Pharmaceuticals Phase 2 Sofpironium Bromide, 15% + Vehicle Botanix Pharmaceuticals Phase 3 BBI-4000 Botanix Pharmaceuticals Phase 1 Sofpironium Bromide Gel, 15% + Vehicle Botanix Pharmaceuticals Phase 3 Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15% Botanix Pharmaceuticals Phase 3 Sofpironium Bromide Gel, 15% Botanix Pharmaceuticals Phase 2
Other Products from GSK plc